Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18511
Country/Region: Kenya
Year: 2018
Main Partner: Christian Health Association of Kenya
Main Partner Program: NA
Organizational Type: FBO
Funding Agency: HHS/CDC
Total Funding: $7,654,026 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $307,779
Care: TB/HIV (HVTB) $488,099
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $656,397
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $588,613
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $5,003,014
Treatment: Pediatric Treatment (PDTX) $610,124
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 9
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 9
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 27
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 27
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 9
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 89
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 89
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 9
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 126
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 126
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 9
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 25
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 25
GEND_GBV 25-29, Male, Physical and/or Emotional Violence 2019 10
GEND_GBV 25-29, Male, Sexual Violence (Post-Rape Care) 2019 10
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 28
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 26
GEND_GBV 30-34, Male, Physical and/or Emotional Violence 2019 9
GEND_GBV 30-34, Male, Sexual Violence (Post-Rape Care) 2019 10
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 27
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 27
GEND_GBV 35-39, Male, Physical and/or Emotional Violence 2019 9
GEND_GBV 35-39, Male, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 27
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 27
GEND_GBV 40-49, Male, Physical and/or Emotional Violence 2019 9
GEND_GBV 40-49, Male, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 9
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2019 10
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2019 9
GEND_GBV 50+, Male, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 57
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 441
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 457
GEND_GBV Number of people receiving post-GBV care 2019 898
HTS_SELF 2019 1,078
HTS_SELF 15-19, Female, Directly-Assisted 2019 59
HTS_SELF 15-19, Female, Unassisted 2019 59
HTS_SELF 15-19, Male, Directly-Assisted 2019 18
HTS_SELF 15-19, Male, Unassisted 2019 18
HTS_SELF 20-24, Female, Directly-Assisted 2019 59
HTS_SELF 20-24, Female, Unassisted 2019 59
HTS_SELF 20-24, Male, Directly-Assisted 2019 18
HTS_SELF 20-24, Male, Unassisted 2019 18
HTS_SELF 25-29, Female, Directly-Assisted 2019 59
HTS_SELF 25-29, Female, Unassisted 2019 59
HTS_SELF 25-29, Male, Directly-Assisted 2019 18
HTS_SELF 25-29, Male, Unassisted 2019 18
HTS_SELF 30-34, Female, Directly-Assisted 2019 59
HTS_SELF 30-34, Female, Unassisted 2019 59
HTS_SELF 30-34, Male, Directly-Assisted 2019 18
HTS_SELF 30-34, Male, Unassisted 2019 18
HTS_SELF 35-39, Female, Directly-Assisted 2019 59
HTS_SELF 35-39, Female, Unassisted 2019 59
HTS_SELF 35-39, Male, Directly-Assisted 2019 18
HTS_SELF 35-39, Male, Unassisted 2019 18
HTS_SELF 40-49, Female, Directly-Assisted 2019 59
HTS_SELF 40-49, Female, Unassisted 2019 58
HTS_SELF 40-49, Male, Directly-Assisted 2019 19
HTS_SELF 40-49, Male, Unassisted 2019 18
HTS_SELF 50+, Female, Directly-Assisted 2019 59
HTS_SELF 50+, Female, Unassisted 2019 59
HTS_SELF 50+, Male, Directly-Assisted 2019 17
HTS_SELF 50+, Male, Unassisted 2019 19
HTS_SELF Directly-Assisted 2019 539
HTS_SELF FSW, Directly-Assisted 2019 723
HTS_SELF MSM, Directly-Assisted 2019 162
HTS_SELF PWID, Directly-Assisted 2019 65
HTS_SELF Unassisted 2019 539
HTS_SELF Unassisted - Other 2019 54
HTS_SELF Unassisted - Self 2019 269
HTS_SELF Unassisted - Sex Partner 2019 217
HTS_TST <5, Unknown Sex, Negative 2019 2
HTS_TST 15-19, Female, Negative 2019 302
HTS_TST 15-19, Male, Negative 2019 143
HTS_TST 20-24, Female, Negative 2019 1,043
HTS_TST 20-24, Male, Negative 2019 458
HTS_TST 25-29, Female, Negative 2019 5,682
HTS_TST 25-29, Female, Negative 2019 432
HTS_TST 25-29, Female, Negative 2019 101
HTS_TST 25-29, Female, Negative 2019 3,370
HTS_TST 25-29, Female, Negative 2019 1,416
HTS_TST 25-29, Female, Negative 2019 7,642
HTS_TST 25-29, Female, Negative 2019 116
HTS_TST 25-29, Female, Negative 2019 13,711
HTS_TST 25-29, Male, Negative 2019 67
HTS_TST 25-29, Male, Negative 2019 132
HTS_TST 25-29, Male, Negative 2019 884
HTS_TST 25-29, Male, Negative 2019 306
HTS_TST 25-29, Male, Negative 2019 1,698
HTS_TST 25-29, Male, Negative 2019 12
HTS_TST 25-29, Male, Negative 2019 10,608
HTS_TST 30-34, Female, Negative 2019 5,679
HTS_TST 30-34, Female, Negative 2019 492
HTS_TST 30-34, Female, Negative 2019 93
HTS_TST 30-34, Female, Negative 2019 4,246
HTS_TST 30-34, Female, Negative 2019 1,615
HTS_TST 30-34, Female, Negative 2019 8,733
HTS_TST 30-34, Female, Negative 2019 133
HTS_TST 30-34, Female, Negative 2019 15,537
HTS_TST 30-34, Male, Negative 2019 78
HTS_TST 30-34, Male, Negative 2019 142
HTS_TST 30-34, Male, Negative 2019 1,137
HTS_TST 30-34, Male, Negative 2019 368
HTS_TST 30-34, Male, Negative 2019 2,040
HTS_TST 30-34, Male, Negative 2019 16
HTS_TST 30-34, Male, Negative 2019 12,515
HTS_TST 35-39, Female, Negative 2019 5,684
HTS_TST 35-39, Female, Negative 2019 124
HTS_TST 35-39, Female, Negative 2019 110
HTS_TST 35-39, Female, Negative 2019 963
HTS_TST 35-39, Female, Negative 2019 405
HTS_TST 35-39, Female, Negative 2019 2,182
HTS_TST 35-39, Female, Negative 2019 33
HTS_TST 35-39, Female, Negative 2019 5,681
HTS_TST 35-39, Male, Negative 2019 78
HTS_TST 35-39, Male, Negative 2019 199
HTS_TST 35-39, Male, Negative 2019 1,061
HTS_TST 35-39, Male, Negative 2019 368
HTS_TST 35-39, Male, Negative 2019 2,040
HTS_TST 35-39, Male, Negative 2019 16
HTS_TST 35-39, Male, Negative 2019 5,324
HTS_TST 40-49, Female, Negative 2019 5,683
HTS_TST 40-49, Female, Negative 2019 124
HTS_TST 40-49, Female, Negative 2019 91
HTS_TST 40-49, Female, Negative 2019 963
HTS_TST 40-49, Female, Negative 2019 405
HTS_TST 40-49, Female, Negative 2019 2,182
HTS_TST 40-49, Female, Negative 2019 33
HTS_TST 40-49, Female, Negative 2019 5,683
HTS_TST 40-49, Male, Negative 2019 1,775
HTS_TST 40-49, Male, Negative 2019 26
HTS_TST 40-49, Male, Negative 2019 183
HTS_TST 40-49, Male, Negative 2019 354
HTS_TST 40-49, Male, Negative 2019 121
HTS_TST 40-49, Male, Negative 2019 678
HTS_TST 40-49, Male, Negative 2019 5
HTS_TST 50+, Female, Negative 2019 60
HTS_TST 50+, Male, Negative 2019 11
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 385,762
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Female, Negative 2019 54
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Male, Negative 2019 65
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Female, Negative 2019 184
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Male, Negative 2019 210
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Female, Negative 2019 17
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Male, Negative 2019 2
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 58
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 4,521
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 13,773
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 155
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 765
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 3,731
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 1,297
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 1,115
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 1,103
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 869
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 3,803
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 3,666
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 203
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 63
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 114
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 565
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 148
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 120
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 7,203
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 3,601
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 24,804
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 11,523
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 1,092
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 342
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 2,445
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 782
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 665
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 11,649
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 14,556
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 59,314
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 28,749
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 2,838
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 888
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 2,968
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 59
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 71
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 64
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 103
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 128
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 104
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 127
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 86
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 151
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 174
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 147
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 3,155
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 1,899
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 10,865
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 6,085
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 482
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 175
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 465
HTS_TST_POS 15-19, Female, Positive 2019 1
HTS_TST_POS 20-24, Female, Positive 2019 5
HTS_TST_POS 25-29, Female, Positive 2019 280
HTS_TST_POS 25-29, Female, Positive 2019 1
HTS_TST_POS 25-29, Female, Positive 2019 20
HTS_TST_POS 25-29, Female, Positive 2019 134
HTS_TST_POS 25-29, Female, Positive 2019 147
HTS_TST_POS 25-29, Female, Positive 2019 105
HTS_TST_POS 25-29, Female, Positive 2019 8
HTS_TST_POS 25-29, Female, Positive 2019 265
HTS_TST_POS 25-29, Male, Positive 2019 31
HTS_TST_POS 25-29, Male, Positive 2019 28
HTS_TST_POS 25-29, Male, Positive 2019 28
HTS_TST_POS 25-29, Male, Positive 2019 15
HTS_TST_POS 25-29, Male, Positive 2019 181
HTS_TST_POS 30-34, Female, Positive 2019 28
HTS_TST_POS 30-34, Female, Positive 2019 1
HTS_TST_POS 30-34, Female, Positive 2019 20
HTS_TST_POS 30-34, Female, Positive 2019 139
HTS_TST_POS 30-34, Female, Positive 2019 166
HTS_TST_POS 30-34, Female, Positive 2019 120
HTS_TST_POS 30-34, Female, Positive 2019 10
HTS_TST_POS 30-34, Female, Positive 2019 296
HTS_TST_POS 30-34, Male, Positive 2019 32
HTS_TST_POS 30-34, Male, Positive 2019 36
HTS_TST_POS 30-34, Male, Positive 2019 34
HTS_TST_POS 30-34, Male, Positive 2019 18
HTS_TST_POS 30-34, Male, Positive 2019 216
HTS_TST_POS 35-39, Female, Positive 2019 24
HTS_TST_POS 35-39, Female, Positive 2019 25
HTS_TST_POS 35-39, Female, Positive 2019 33
HTS_TST_POS 35-39, Female, Positive 2019 40
HTS_TST_POS 35-39, Female, Positive 2019 29
HTS_TST_POS 35-39, Female, Positive 2019 3
HTS_TST_POS 35-39, Female, Positive 2019 106
HTS_TST_POS 35-39, Male, Positive 2019 43
HTS_TST_POS 35-39, Male, Positive 2019 36
HTS_TST_POS 35-39, Male, Positive 2019 35
HTS_TST_POS 35-39, Male, Positive 2019 18
HTS_TST_POS 35-39, Male, Positive 2019 93
HTS_TST_POS 40-49, Female, Positive 2019 105
HTS_TST_POS 40-49, Female, Positive 2019 14
HTS_TST_POS 40-49, Female, Positive 2019 19
HTS_TST_POS 40-49, Female, Positive 2019 32
HTS_TST_POS 40-49, Female, Positive 2019 40
HTS_TST_POS 40-49, Female, Positive 2019 29
HTS_TST_POS 40-49, Female, Positive 2019 3
HTS_TST_POS 40-49, Male, Positive 2019 33
HTS_TST_POS 40-49, Male, Positive 2019 40
HTS_TST_POS 40-49, Male, Positive 2019 12
HTS_TST_POS 40-49, Male, Positive 2019 11
HTS_TST_POS 40-49, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Female, Positive 2019 14
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Male, Positive 2019 10
HTS_TST_POS Service Delivery Point (Community) Index Mod: 50+, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 32
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 137
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 23
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 115
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 76
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 383
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 245
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 19
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 71
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 29
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 250
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 94
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 14
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 34
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 209
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 241
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 1,044
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 471
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 53
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 21
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 30
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 21
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 30
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 34
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 108
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 67
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 370
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 207
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 17
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 4
OVC_SERV Age/Sex: <1 2019 20
OVC_SERV Age/Sex: 1-9 2019 1,614
OVC_SERV Age/Sex: 10-14 Female 2019 1,166
OVC_SERV Age/Sex: 10-14 Male 2019 1,019
OVC_SERV Age/Sex: 15-17 Female 2019 825
OVC_SERV Age/Sex: 15-17 Male 2019 651
OVC_SERV By: Age/sex: 18-24 Female 2019 564
OVC_SERV By: Age/sex: 25+ Female 2019 3
OVC_SERV By: Age/sex: Male 18-24 2019 482
OVC_SERV By: Age/sex: Male 25+ 2019 2
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2019 6,349
OVC_SERV Program Completion: Active 2019 6,338
OVC_SERV Program Completion: Graduation 11 Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner. 5,296 Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2019 6,349
OVC_SERV Sum of Age/Sex disaggregates 2019 3,661
PMTCT_ART Already on ART at beginning of current pregnancy 2019 1,692
PMTCT_ART New on ART 2019 487
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 2,179
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 43,350
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 233
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 233
PMTCT_EID Sum of Infant Age disaggregates 2019 233
PMTCT_STAT 25-29, Female 2019 6,018
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 338
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 5,617
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 63
PMTCT_STAT 30-34, Female 2019 6,969
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 338
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 6,568
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 63
PMTCT_STAT 35-39, Female 2019 6,018
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 338
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 5,617
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 63
PMTCT_STAT 40-49, Female 2019 5,716
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 338
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 5,315
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 63
PMTCT_STAT By Age (Numerator): 10-14 2019 17
PMTCT_STAT By Age (Numerator): 15-19 2019 4,513
PMTCT_STAT By Age (Numerator): 20-24 2019 14,099
PMTCT_STAT By Number of known positives: 15-19 2019 33
PMTCT_STAT By Number of known positives: 20-24 2019 320
PMTCT_STAT By Number of new negative: 10-14 2019 17
PMTCT_STAT By Number of new negative: 15-19 2019 4,452
PMTCT_STAT By Number of new negative: 20-24 2019 13,606
PMTCT_STAT By Number of new positives: 15-19 2019 28
PMTCT_STAT By Number of new positives: 20-24 2019 173
PMTCT_STAT Number of new ANC and L&D clients 2019 43,885
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 43,350
PMTCT_STAT_den 25-29, Female 2019 6,081
PMTCT_STAT_den 30-34, Female 2019 6,081
PMTCT_STAT_den 35-39, Female 2019 6,081
PMTCT_STAT_den 40-49, Female 2019 6,081
PMTCT_STAT_den By Age (Denominator): <15-19 2019 5,086
PMTCT_STAT_den By Age (Denominator): 10-14 2019 27
PMTCT_STAT_den By Age (Denominator): 20-24 2019 14,448
PrEP_NEW 25-29, Female 2019 72
PrEP_NEW 25-29, Male 2019 33
PrEP_NEW 30-34, Female 2019 59
PrEP_NEW 30-34, Male 2019 45
PrEP_NEW 35-39, Female 2019 54
PrEP_NEW 35-39, Male 2019 43
PrEP_NEW 40-49, Female 2019 54
PrEP_NEW 40-49, Male 2019 34
PrEP_NEW Female 15-19 2019 128
PrEP_NEW Female 20-24 2019 436
PrEP_NEW Female 50+ 2019 19
PrEP_NEW FSW 2019 151
PrEP_NEW Male 15-19 2019 9
PrEP_NEW Male 20-24 2019 61
PrEP_NEW Male 50+ 2019 17
PrEP_NEW MSM 2019 72
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 1,064
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 574
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 725
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 1,299
TB_PREV By Age/Sex (Numerator): <15, Female 2019 579
TB_PREV By Age/Sex (Numerator): <15, Male 2019 557
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 8,883
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 4,246
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 14,265
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 14,976
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 660
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 624
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 9,308
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 4,372
TB_PREV_den IPT, Life-long ART, New, Positive 2019 15,521
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 126
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 947
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 139
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,802
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 3,014
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 3,047
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 126
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 957
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 138
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,826
TX_CURR 25-29, Female, Positive 2019 10,138
TX_CURR 25-29, Male, Positive 2019 2,134
TX_CURR 30-34, Female, Positive 2019 7,689
TX_CURR 30-34, Male, Positive 2019 3,335
TX_CURR 35-39, Female, Positive 2019 7,690
TX_CURR 35-39, Male, Positive 2019 3,335
TX_CURR 40-49, Female, Positive 2019 5,243
TX_CURR 40-49, Male, Positive 2019 3,335
TX_CURR Age/Sex: <1 2019 41
TX_CURR Age/Sex: <1-9 2019 1,680
TX_CURR Age/Sex: 10-14 Female 2019 1,060
TX_CURR Age/Sex: 10-14 Male 2019 1,057
TX_CURR Age/Sex: 15-19 Female 2019 1,425
TX_CURR Age/Sex: 15-19 Male 2019 853
TX_CURR Age/Sex: 20-24 Female 2019 3,965
TX_CURR Age/Sex: 20-24 Male 2019 1,137
TX_CURR Age/Sex: 50+ Female 2019 4,195
TX_CURR Age/Sex: 50+ Male 2019 1,206
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 59,524
TX_CURR Sum of age/sex disaggregates 2019 2,278
TX_NEW 25-29, Female, Positive 2019 852
TX_NEW 25-29, Male, Positive 2019 196
TX_NEW 30-34, Female, Positive 2019 970
TX_NEW 30-34, Male, Positive 2019 251
TX_NEW 35-39, Female, Positive 2019 239
TX_NEW 35-39, Male, Positive 2019 233
TX_NEW 40-49, Female, Positive 2019 237
TX_NEW 40-49, Male, Positive 2019 77
TX_NEW Breastfeeding status 2019 99
TX_NEW By Age/Sex: <1 2019 75
TX_NEW By Age/Sex: 1-9 2019 121
TX_NEW By Age/Sex: 10-14 Female 2019 46
TX_NEW By Age/Sex: 10-14 Male 2019 32
TX_NEW By Age/Sex: 15-19 Female 2019 734
TX_NEW By Age/Sex: 15-19 Male 2019 388
TX_NEW By Age/Sex: 20-24 Female 2019 2,524
TX_NEW By Age/Sex: 20-24 Male 2019 1,242
TX_NEW By Age/Sex: 50+ Female 2019 122
TX_NEW By Age/Sex: 50+ Male 2019 36
TX_NEW By Key populations: People who inject drugs (PWID) 2019 2
TX_NEW FSW 2019 87
TX_NEW MSM 2019 31
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 8,381
TX_NEW People in prisons and other enclosed settings 2019 69
TX_NEW Pregnancy status 2019 563
TX_NEW Sum of Age/Sex disaggregates 2019 5,124
TX_NEW TG 2019 2
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 60,201
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 939
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 168
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 937
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 162
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 35,641
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 6,284
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 13,655
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 2,411
TX_PVLS_den Denominator: Indication: Routine 2019 51,173
TX_PVLS_den Denominator: Indication: Targeted 2019 9,030
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 3,822
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 2,910
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 6,732
TX_RET Numerator by Status: Breastfeeding 2019 68
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 6,953
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 3,945
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 3,008
TX_RET_den Denominator by Status: Breastfeeding 2019 76
TX_RET_den Denominator by Status: Pregnant 2019 565
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 59,519
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 2,111
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 2,264
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 37,656
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 17,489
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 1,204
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 220
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 1,510
Cross Cutting Budget Categories and Known Amounts Total: $3,328,680
Gender: Gender Based Violence (GBV) $194,651
GBV Prevention
Implementation
Capacity building
Post GBV Care
Implementation
Capacity building
Motor Vehicles: Purchased $300,000
Human Resources for Health $2,834,029